HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools...
Diagnostics
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care productsMOUNTAIN VIEW, Calif., April 06, 2023...
UPDATE–Nox Medical Secures New Patent for Calculating Respiratory Effort During Sleep Studies
NoxT3s NoxT3sALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Nox Medical has secured a new patent to measure breathing movements...
Eurobio Scientific : 2022 ANNUAL RESULTS – Very strong performance and strengthening of the Core Business
2022 ANNUAL RESULTS Very strong performance and strengthening of the Core Business Core Business1 revenues up 15% to €93.5M (+53%...
OXOS Medical Raises $23M Series A to Deliver “Radiology Department in a Box” to the Entire Healthcare Value Chain
Co-led by Parkway Venture Capital and Intel Capital, OXOS will leverage funds to expand into clinical, mobile, and home care...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousandROCKVILLE, Md., April...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place...
Notice convening the Annual General Meeting in BioPorto A/S
April 5, 2023Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes...
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
BERLIN and INDIANAPOLIS, April 04, 2023 (GLOBE NEWSWIRE) -- Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT...
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
Common Stock Offering Priced At-The-MarketIRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a...
StageZero to Issue Q4 2022 Financial Results on Friday March 31
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...
Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders
Company Announcement, Helsinki, 31 March 2023 at 1 PM (EEST) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders...
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the fourth QIAGEN instrument to receive...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the...
Press release Biocartis Group NV: Biocartis To Publish 2022 Annual Report on 11 April 2023
PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023...
Lucira Health Announces U.S. Launch of First & Only At-Home Combination COVID-19 & Flu Test Amidst Sale Process
Combination Test Also Secures Point-Of-Care Authorization in Australia Lucira COVID-19 & Flu Home Test – The First & Only Combination...
HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health...
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,...